NATCO Pharma announced that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Active Pharmaceutical
Ingredient Division located in Manali, Chennai from 17 November – 21 November 2025. The Company received seven (7) observation in the Form-483.
Further, the Company has received the EIR (Establishment Inspection
Report) from the USFDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI).